Wegovy alternatives at a glance
Wegovy is semaglutide, a GLP-1 receptor agonist that FDA approved in June 2021 as a once-weekly injection for long-term weight management. Its label covers adults and children 12 and older with obesity, and adults with overweight plus at least one condition tied to weight.
Wegovy alternatives come in two kinds: semaglutide in another form, or a different drug that acts on the GLP-1 receptor, sometimes with a second receptor added. Six are below, and each one needs a prescription. Harbor's compounded semaglutide and tirzepatide, which are not FDA approved, come first: one weekly injection at home, with medication, clinician care and check-ins in one flat price, and a licensed clinician who decides whether treatment fits.
| Option | Active drug | FDA status for weight | How it is taken |
|---|---|---|---|
| Wegovy injection (reference) | Semaglutide | Approved, ages 12 and up | Injection, once a week |
| Compounded semaglutide | Semaglutide | Not FDA approved | Injection, once a week |
| Compounded tirzepatide | Tirzepatide | Not FDA approved | Injection, once a week |
| Zepbound | Tirzepatide | Approved, adults | Injection, once a week |
| The Wegovy pill | Semaglutide | Approved, adults | Tablet each morning, empty stomach |
| Foundayo | Orforglipron | Approved, adults | Tablet once a day, with or without food |
| Saxenda | Liraglutide | Approved, ages 12 and up | Injection, once a day |
Approval status and schedules from each current FDA label on DailyMed, read November 16, 2026. Compounded drugs are not FDA approved and carry no FDA label.
Alternatives to Wegovy for weight loss
These six alternatives to Wegovy begin with two weekly compounded injections, semaglutide and tirzepatide, which are not FDA approved and which a clinician can review online. Four brand drugs follow, each described from its current FDA label.
Trial figures in the brand entries come from separate trials of brand drugs, each with its own length and population, so read them as context and not as a ranking. None of those label trials tested a compounded drug. For the injection being replaced, see MedlinePlus semaglutide injection facts.
Compounded semaglutide
Weekly GLP-1 injection, not FDA approved
Compounded semaglutide keeps the once-weekly semaglutide routine at a cash price that does not depend on insurance. It is a compounded drug, not FDA approved and not the same product as Wegovy, and the Wegovy trials tested the brand drug only.
Where it wins
What it costs you
Weekly semaglutide at one flat monthly price
Compounded tirzepatide
Weekly GIP and GLP-1 injection, not FDA approved
Compounded tirzepatide suits a reader whose clinician recommends a two-pathway approach, since tirzepatide acts on GIP and GLP-1 receptors where semaglutide acts on GLP-1 alone. It is a compounded drug, not FDA approved and not the same product as Zepbound.
Where it wins
What it costs you
A weekly two-pathway option
Zepbound
Tirzepatide, a GIP and GLP-1 agonist
Zepbound is brand tirzepatide, FDA approved on November 8, 2023, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition. Its label also covers moderate to severe obstructive sleep apnea in adults with obesity.
Where it wins
What it costs you
When your plan covers brand tirzepatide
The Wegovy pill
Semaglutide tablet, FDA approved 2025
The Wegovy pill is semaglutide as a once-daily tablet, FDA approved on December 22, 2025. Its label covers long-term weight management in adults, and lowering the risk of major cardiovascular events in adults with heart disease and obesity or overweight.
Where it wins
What it costs you
Staying on brand semaglutide without injections
Foundayo
Orforglipron tablet, FDA approved 2026
Foundayo (orforglipron) is a once-daily GLP-1 pill that FDA approved on April 1, 2026, for long-term weight management in adults with obesity, or with overweight and at least one weight-related condition.
Where it wins
What it costs you
A daily pill with no food timing
Saxenda
Liraglutide injection, FDA approved 2014
Saxenda is liraglutide 3 mg, a GLP-1 receptor agonist injected once a day. Approved on December 23, 2014, it is the oldest approval on this list, and a generic liraglutide injection with the same weight-management indication is now listed on DailyMed.
Where it wins
What it costs you
When a generic GLP-1 matters most
How to choose a Wegovy alternative
Start with the reason Wegovy is not working out, because each reason points to a different Wegovy alternative.
| Your reason | Options to raise with a clinician |
|---|---|
| Cost, or no coverage | Compounded semaglutide in a cash-pay program (not FDA approved), or the brand your plan does cover |
| You want a different drug | Compounded tirzepatide (not FDA approved) or Zepbound |
| You want a pill | The Wegovy pill or Foundayo |
| You want an FDA-approved generic | Generic liraglutide, the drug in Saxenda |
A starting point for the conversation, not a prescription. Harbor offers the two compounded injections, and no pill or brand drug.
If the problem is paying for Wegovy without insurance, coverage is uneven to begin with. NIDDK notes that some, but not all, insurance plans cover weight management medications. A cash-pay program removes the coverage question, though never the prescription.
Compounded drugs are not FDA approved, and FDA advises getting a prescription and filling it at a state-licensed pharmacy. Whether a compounded drug fits you is the prescribing clinician's call. Both routes are laid out in compounded vs brand semaglutide.
What a clinician checks first
Every drug on this list is ruled out by a personal or family history of medullary thyroid carcinoma or MEN 2. The brand labels also advise against combining one GLP-1 drug with another, so this is a switch and never an add-on. The compounded programs are for adults 18 and older and are not available during pregnancy, breastfeeding or while planning a pregnancy. For your own history, message your clinician.
Compounded semaglutide shots with Harbor
For a reader leaving Wegovy over cost or coverage, the closest routine is another weekly semaglutide injection. Harbor compounded semaglutide, which is not FDA approved, is a once-weekly injection you give yourself at home, in a program that puts medication, clinician care and check-ins in one price, from $89 a month, that stays flat as your dose goes up. No insurance is required, and HSA and FSA cards are accepted.
It is not Wegovy, and it is not a generic of it. A board-certified physician licensed in your state reviews your intake and decides whether treatment is appropriate before anything ships. If a clinician does not approve treatment, the payment is refunded in full.
If you are comparing places to get semaglutide online, the order of steps tells you a lot: intake, physician review, then shipment. When you switch in, you list your current medication, your dose and the date of your last injection, and the provider makes the final call on where you start.
The compounded semaglutide shots, which are not FDA approved, arrive as a multi-dose vial with U-100 insulin syringes, alcohol prep pads and a sharps container. Kendra Freeman described the pricing on Trustpilot in August 2026: "Needing to up your dose great no problem costs stay the same."
This program is also designed to end. When you reach your goal, it moves to a structured, clinician-guided taper and registered-dietitian aftercare. The online quiz takes about 90 seconds and is the first step toward a physician review.
Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Harbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who determine whether treatment is appropriate. Compounded medications are not FDA approved and are not reviewed by the FDA for safety or effectiveness.
Frequently asked questions
No. As of November 2026, Drugs@FDA lists no approved generic of the Wegovy injection or the Wegovy tablets. One generic semaglutide injection holds a tentative approval dated April 7, 2026, in the strengths of Ozempic pens, and FDA says a tentative approval does not allow a product to be marketed. Compounded semaglutide is not FDA approved and is not a generic. Neither is a supplement sold as a natural alternative to Wegovy, since FDA does not approve dietary supplements for safety or effectiveness before they are sold.
No. On compounded semaglutide vs Wegovy, the difference is regulatory and practical. Wegovy is an FDA-approved product with its own pens, tablets and label trials, while a compounded drug is not FDA approved and is not reviewed by FDA for safety, effectiveness or quality before it is marketed. Compounded formulations may also differ in concentration, inactive ingredients, delivery system or preparation method. FDA lists a claim that a compounded drug is the same as an FDA-approved drug among its warning signs for online sellers.
Yes, although every option here still needs a prescription. NIDDK notes that some, but not all, insurance plans cover weight management medications, and suggests asking your insurer what your plan covers. If you pay cash, a compounded semaglutide program starts at $89 a month (compounded, not FDA approved), requires no insurance and accepts HSA and FSA cards.
Sources
- Wegovy (semaglutide) injection and tablets label, DailyMed.
- Wegovy injection NDA 215256 approval history, Drugs@FDA.
- Wegovy tablets NDA 218316 approval history, Drugs@FDA.
- Zepbound (tirzepatide) label, DailyMed.
- Zepbound NDA 217806 approval history, Drugs@FDA.
- SURMOUNT-5, tirzepatide compared with semaglutide (NCT05822830), ClinicalTrials.gov.
- Foundayo (orforglipron) tablets label, DailyMed.
- FDA approves Foundayo (orforglipron), April 1, 2026.
- Saxenda (liraglutide) label, DailyMed.
- Saxenda NDA 206321 approval history, Drugs@FDA.
- Liraglutide injection (generic, weight management) label, DailyMed.
- Generic semaglutide injection ANDA 220314, tentative approval, Drugs@FDA.
- Drugs@FDA glossary of terms: generic drug, tentative approval.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss.
- FDA 101: Dietary supplements.
- Prescription medications to treat overweight and obesity, NIDDK.
- Semaglutide injection, MedlinePlus drug information.






